CA2231330A1 - Dosage a rendement eleve utilisant des proteines hybrides - Google Patents
Dosage a rendement eleve utilisant des proteines hybrides Download PDFInfo
- Publication number
- CA2231330A1 CA2231330A1 CA 2231330 CA2231330A CA2231330A1 CA 2231330 A1 CA2231330 A1 CA 2231330A1 CA 2231330 CA2231330 CA 2231330 CA 2231330 A CA2231330 A CA 2231330A CA 2231330 A1 CA2231330 A1 CA 2231330A1
- Authority
- CA
- Canada
- Prior art keywords
- fusion protein
- recited
- protein
- binding
- expression vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9493—Immunosupressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Abstract
L'invention porte sur un dosage à rendement élevé utilisé pour sélectionner des composés capables de se lier à une protéine hybride composée d'une protéine-cible et d'une protéine fixant FK506. L'invention concerne également le procédé de préparation de l'ADN codant la protéine hybride, et d'expression de cet ADN. L'invention se rapporte également aux séquences protéiques et d'ADN de recombinaison pour plusieurs protéines hybrides.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US381995P | 1995-09-15 | 1995-09-15 | |
US60/003,819 | 1995-09-15 | ||
GBGB9605210.5A GB9605210D0 (en) | 1996-03-12 | 1996-03-12 | A high throughput assay using fusion proteins |
GB9605210.5 | 1996-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2231330A1 true CA2231330A1 (fr) | 1997-03-20 |
Family
ID=26308918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA 2231330 Abandoned CA2231330A1 (fr) | 1995-09-15 | 1996-09-11 | Dosage a rendement eleve utilisant des proteines hybrides |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0871648A1 (fr) |
JP (1) | JPH11513246A (fr) |
CA (1) | CA2231330A1 (fr) |
WO (1) | WO1997010253A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997039326A2 (fr) * | 1996-04-18 | 1997-10-23 | Ariad Pharmaceuticals, Inc. | Dosage in vitro a polarisation de fluorescence |
US6962982B2 (en) | 2001-06-22 | 2005-11-08 | Roche Diagnostics Corporation | Soluble complexes of target proteins and peptidyl prolyl isomerase chaperones and methods of making and using them |
US7094757B2 (en) | 2001-06-22 | 2006-08-22 | Roche Diagnostics Corporation | Complexes comprising a prion protein and a peptidyl prolyl isomerase chaperone, and method for producing and using them |
JP4168028B2 (ja) * | 2002-06-25 | 2008-10-22 | 積水化学工業株式会社 | 発現ベクター、宿主、融合タンパク質、融合タンパク質の製造方法及びタンパク質の製造方法 |
JP4871960B2 (ja) | 2006-01-03 | 2012-02-08 | エフ.ホフマン−ラ ロシュ アーゲー | 優れたシャペロン活性およびフォールディング活性を有するキメラ融合タンパク質 |
JP2022553409A (ja) * | 2019-10-23 | 2022-12-22 | スティヒティング ヘット ネーデルランズ カンケル インスティテュート-アントニ ファン レーウェンフーク ジーケンハウス | 免疫細胞制御用キメラポリペプチド |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69230433D1 (de) * | 1991-01-18 | 2000-01-20 | Univ New York | Cdns-klonierungsverfahren für rezeptortyrosinkinasezielprotein und hgrb-proteine |
US5352660A (en) * | 1991-10-31 | 1994-10-04 | Mount Sinai Hospital Corporation | Method for assaying for a substance that affects a SH2-phosphorylated ligand regulatory system |
US5498597A (en) * | 1992-01-17 | 1996-03-12 | Dana-Farber Cancer Institute, Inc. | FKBP-13, an FK506-binding immunophilin |
GB9210176D0 (en) * | 1992-05-12 | 1992-06-24 | Cemu Bioteknik Ab | Chemical method |
US5464745A (en) * | 1993-03-31 | 1995-11-07 | Novagen, Inc. | Protein ligand binding region mapping system |
US5580979A (en) * | 1994-03-15 | 1996-12-03 | Trustees Of Tufts University | Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions |
-
1996
- 1996-09-11 EP EP96935808A patent/EP0871648A1/fr not_active Withdrawn
- 1996-09-11 WO PCT/US1996/014567 patent/WO1997010253A1/fr not_active Application Discontinuation
- 1996-09-11 JP JP9512071A patent/JPH11513246A/ja active Pending
- 1996-09-11 CA CA 2231330 patent/CA2231330A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1997010253A1 (fr) | 1997-03-20 |
JPH11513246A (ja) | 1999-11-16 |
EP0871648A1 (fr) | 1998-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Scott et al. | Reversible phosphorylation at the C-terminal regulatory domain of p21Waf1/Cip1 modulates proliferating cell nuclear antigen binding | |
Schaller et al. | Autophosphorylation of the focal adhesion kinase, ppl25FAK, directs SH2-dependent binding of pp60src | |
US5783398A (en) | High throughput assay using fusion proteins | |
Phizicky et al. | Protein-protein interactions: methods for detection and analysis | |
Warbrick et al. | Homologous regions of Fen1 and p21Cip1 compete for binding to the same site on PCNA: a potential mechanism to co-ordinate DNA replication and repair | |
Thomas et al. | The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin | |
Lamphere et al. | Interaction between Cdc37 and Cdk4 in human cells | |
US9874567B2 (en) | Kits to assay kinase activity | |
Andjelković et al. | The catalytic subunit of protein phosphatase 2A associates with the translation termination factor eRF1. | |
US5776696A (en) | High throughput assay using fusion proteins | |
Trinkle-Mulcahy et al. | Nuclear organisation of NIPP1, a regulatory subunit of protein phosphatase 1 that associates with pre-mRNA splicing factors | |
EP1098967B1 (fr) | Procede de detection d'interactions proteine-proteine et kit d'utilisation | |
Yeow-Fong et al. | SNX9 as an adaptor for linking synaptojanin-1 to the Cdc42 effector ACK1 | |
Becker et al. | Expression of a tyrosine phosphorylated, DNA binding Stat3β dimer in bacteria | |
AU726294B2 (en) | Ikk-alpha proteins, nucleic acids and methods | |
US7132278B2 (en) | PAS kinase | |
CA2231330A1 (fr) | Dosage a rendement eleve utilisant des proteines hybrides | |
WO1997010502A1 (fr) | Dosage a rendement eleve utilisant des proteines de fusion | |
Kim et al. | Modulation of EWS/WT1 activity by the v-Src protein tyrosine kinase | |
US5874230A (en) | Assays using TRAF2-associated protein kinase polypeptides | |
US20050283003A1 (en) | Reversible immobilization of arginine-tagged moieties on a silicate surface | |
WO1998041866A1 (fr) | Dosage a haute capacite dans lequel des proteines de fusion sont utilisees | |
US20100029507A1 (en) | The biochip for the detection of phosphorylation and the detection method using the same | |
Sonatore et al. | The utility of FK506-binding protein as a fusion partner in scintillation proximity assays: application to SH2 domains | |
Brown | Integration of Heterotrimeric G Protein Signaling by the Regulator of G Protein Signaling 14 (RGS14): Independent Regulation of Gα Signaling by the RGS Domain and GPR Motif by the RGS domain and GPR motif |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |